Peter Duncan Neuroscience homepage

Neuroinflammation Group

Neurodegenerative Diseases Group

HIV Neurosciences Group

 

Clinical Trials Group: Dr. Justin Garber MBBS, Thomas Gates MPsych, Fiona Kilkenny RN CNS, Kyle MacDonald RN MNursing, Dr. Jennifer Menon DPsych

Research fields:Neuro7

  • Commercially-driven Phase II and Phase III research investigating potential drug treatments for Alzheimer’s disease (AD), mild cognitive impairment, and prodromal AD
  • Incorporates recent advances in neurocognitive testing, screening and neuroimaging techniques (MRI, PET).
  • Clinical trials in HIV treatment optimisation in relation to HIV-associated Neurocognitive Disorders.
  • Investigating measurable biomarkers of HIV latency in the Central Nervous System.

 


Selected Publications

  1. Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ. Maraviroc-Intensified cART Improves Cognition in Virally Suppressed HAND: A Pilot Randomized-Controlled Trial. AIDS 2016;30(4):591-600INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med. 2015 Apr;16 Suppl 1:1-9.
  2. Wright EJ, Grund B, Cysique L, Robertson K, Brew BJ, Collins G, Shlay J, Winston A, Read T, Price RW, on behalf of the INSIGHT START study team. Factors associated with neurocognitive test performance at baseline in the INSIGHT START study, HIV Medicine 2015 Apr;16 Suppl S1:97-108.
  3. Wright EJ, Robertson K, Grund B, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha M, Hoy J, Miller C, de Oliviera A, Pumpradit W, Shlay J, El-Sadr W, Price RW for the INSIGHT SMART Study Group. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV + persons. Neurology 2010;75:864–873.

 

For more information